Trials / Active Not Recruiting
Active Not RecruitingNCT07185776
A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-5632 Injection in Adult Patients at High Risk of Cardiovascular Events With Elevated Lipoprotein(a)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of HRS-5632 in adult participants with elevated Lipoprotein(a) (Lp(a)) at high risk for cardiovascular events.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-5632 Injection | HRS-5632 injection. |
| DRUG | HRS-5632 Injection Placebo | HRS-5632 injection placebo. |
Timeline
- Start date
- 2025-10-21
- Primary completion
- 2027-04-01
- Completion
- 2027-10-01
- First posted
- 2025-09-22
- Last updated
- 2026-03-05
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07185776. Inclusion in this directory is not an endorsement.